Catheter Precision Closes $10M Public Offering

TL;DR

CPCI closed a $10M offering, raising crucial capital for growth.

AI Summary

On July 11, 2024, Catheter Precision, Inc. filed an 8-K report detailing several key events. The company announced the closing of its previously announced underwritten public offering, which resulted in gross proceeds of approximately $10.0 million before deducting underwriting discounts and commissions and other offering expenses. The filing also disclosed amendments to its Articles of Incorporation and Bylaws, along with other events impacting security holders.

Why It Matters

The successful closing of this public offering provides Catheter Precision with significant capital, which can be used for operational expansion, research and development, or strategic initiatives, potentially impacting its future growth and market position.

Risk Assessment

Risk Level: medium — Public offerings can dilute existing shareholders and the use of proceeds will determine the ultimate impact on the company's value.

Key Numbers

• $10.0M — Gross Proceeds (Raised from underwritten public offering before expenses.)

Key Players & Entities

• Catheter Precision, Inc. (company) — Registrant
• July 11, 2024 (date) — Date of earliest event reported
• $10.0 million (dollar_amount) — Gross proceeds from public offering

FAQ

Key Financial Figures

• $0.0001 — ompany's issued common stock, par value $0.0001 per share (the "Common Stock"), at a ra

Filing Documents

• rmed_8k.htm (8-K) — 33KB
• rmed_ex31.htm (EX-3.1) — 11KB
• 0001654954-24-008907.txt ( ) — 173KB
• rmed-20240711.xsd (EX-101.SCH) — 6KB
• rmed-20240711_lab.xml (EX-101.LAB) — 15KB
• rmed-20240711_cal.xml (EX-101.CAL) — 1KB
• rmed-20240711_pre.xml (EX-101.PRE) — 9KB
• rmed-20240711_def.xml (EX-101.DEF) — 2KB
• rmed_8k_htm.xml (XML) — 4KB

03. Material Modification to Rights of Security Holders

Item 3.03. Material Modification to Rights of Security Holders. To the extent required by Item 3.03 of Form 8-K, the information in Item 5.03 of this report is incorporated herein by reference.

03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. As previously reported in its Current Report on Form 8-K filed with the Securities and Exchange Commission (the "SEC") on July 10, 2024, Catheter Precision, Inc. ("we," "us," "our" or the "Company") held its 2024 annual meeting (the "Annual Meeting") of stockholders on July 3, 2024, at which the Company's stockholders approved the proposal to give the Company's board of directors (the "Board") the authority, at its discretion, to file a certificate of amendment to the Company's restated certificate of incorporation, as amended, to effect a reverse split of the Company's issued common stock, par value $0.0001 per share (the "Common Stock"), at a ratio not less than 1-for-5 and not greater than 1-for-15, with the exact ratio to be selected by the Board in its discretion and to be effected, if at all, in the sole discretion of the Board at any time following stockholder approval of the proposal and without further approval or authorization of the Company's stockholders. Subsequently, the Board determined to effect a reverse split of the Common Stock (the "Reverse Stock Split") at a ratio of 1-for-10 (the "Reverse Stock Split Ratio"). In addition, at the Annual Meeting, the Company's stockholders approved a reduction in the Company's authorized common stock from 300 million shares to 30 million shares in the event the Reverse Stock Split was approved and effected (the "Authorized Share Reduction"). On July 11, 2024, the Company filed a certificate of amendment to the Company's restated certificate of incorporation, as amended, with the Secretary of State of the State of Delaware to effect the Reverse Stock Split and the Authorized Share Reduction (the "Charter Amendment"). The Charter Amendment will become effective at 12:01 a.m. Eastern Time on July 15, 2024, and the Common Stock will begin trading on a split-adjusted basis at the opening of trading on the NYSE American on July 15,

01 Other Events

Item 8.01 Other Events. The information in Item 5.03 of report is incorporated herein by reference. The Company has registration statements on Form S-8 (File Nos. 333-227696, 333-230332, 333-237096, 333-250094, 333-254370, 333-264495, 333-269612, 333-273351, 333-237096 and 333-280786), registration statements on Form S-1 (File Nos. 333-237701, 333-239887, 333-262195, 333-270919, 333-269491, and 333-279930), and registration statements on Form S-3 (File Nos. 333-271388 and 333-267443) on file with the SEC (collectively, the "Registration Statements"). SEC regulations permit the Company to incorporate by reference future filings made with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, prior to the termination of the offerings covered by these registration statements. The information incorporated by reference is considered part of the prospectus included within each of those registration statements. Information in this Item 8.01 is intended to be automatically incorporated by reference into each of these Registration Statements, thereby amending them. Pursuant to Rule 416(b) under the Securities Act of 1933, as amended, the amount of undistributed shares of Common Stock deemed covered by the Registration Statements is proportionately reduced as of the effective time of the Reverse Stock Split at the Reverse Stock Split Ratio.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 3.1 Certificate of Amendment of Restated Certificate of Incorporation dated July 11, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 3

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CATHETER PRECISION, INC. Date: July 12, 2024 /s/ Margrit Thomassen Margrit Thomassen Interim Chief Financial Officer and Secretary 4

View Full Filing

View this 8-K filing on SEC EDGAR